Abstract: The present disclosure provides a pyrazine compound, a stereoisomer, and a tautomer, and a pharmaceutically acceptable salt thereof in treating a neurodegenerative disease (ND) including Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal dementia (FTD), vascular dementia, HIV-related dementia, multiple sclerosis, progressive lateral sclerosis, Friedreich's ataxia, neuropathic pain, or glaucoma, diabetes mellitus (DM) and a DM-related complication, an inflammation, an oxidative damage, and a mitochondrial disorder-related disease.